Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expanded Customer Base, Multiple Collaborations, Fulfillment of Researchers’ Needs

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced that two of its four subsidiaries, Soluble Biotech and TumorGenesis, are expanding their services with the construction of new good manufacturing practices (“GMP”) laboratories. For Soluble Biotech, the GMP facility ramps up its formulation solutions and stability services so the company can rapidly provide clinical-trial-ready formulations to its customers. The lab will also be utilized to produce proprietary media used in its chromatography kits. A recent article reads, “Dr. Larry DeLucas, VP of Operations at Predictive Oncology, said he expects the new GMP capabilities to ‘significantly increase the potential customer base and lead to multiple long-term collaborations.’” TumorGenesis will use its new lab to produce media as well, among other things. “According to Predictive Oncology Senior VP of Research and Development Richard Gabriel, the company scaling into GMP production of media means that it will be able to meet the needs of researchers.”

To view the full article, visit https://ibn.fm/GvHPf

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical, and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins, including vaccines, antibodies, large and small proteins, and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Announces Q1 2021 Financial Results

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator and house of premium brands, today announced its 2021 first quarter financial results and subsequent events. “This was another great quarter for the company as we continued to see strong traction for our brands,” said Brad Rogers, RWB’s chairman & CEO. “We are building on that momentum and working towards finalizing our revised asset purchase of our Michigan investee to bring their revenue, as well as adjusted sales into IFRS revenue format before the end of this current quarter. Once complete, and the expansion of our Florida operations come on stream, we can finally report in our quarterly results the strength of what we have built and accomplished thus far.”

To view the full press release, visit https://ibn.fm/EBmYk

About Red White & Bloom Brands Inc.

The company is positioning itself to be one of the top three multistate cannabis operators active in the U.S. legal cannabis and hemp sector. RWB is predominantly focusing its investments on the major U.S. markets, including Michigan, Illinois, Massachusetts, Arizona and California with respect to cannabis, and the U.S. and internationally for hemp-based CBD products. For more information about the company, visit www.RedWhiteBloom.com.

NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Red White & Bloom Brands Inc. RWBYF | Leave a comment

MissionIRNewsBreaks – Splash Beverage Group Inc.’s (NYSE American: SBEV) SALT Tequila to be Launched by Leading Distributor in Florida’s Treasure Coast

Splash Beverage Group (NYSE American: SBEV), a portfolio company of leading beverage brands, today announced that Southern Eagle Distributing, the leading beverage distributor in Florida’s Treasure Coast, will market and distribute SALT Tequila to more than 2,000 retailers in its service territory this summer through numerous planned launch activities and events. “When we acquired Copa di Vino, the leading producer of premium wine by the glass in the U.S., not only did we get an iconic brand, we got access to a network of retail locations, ecommerce outlets and 82 Anheuser Busch distributors, which are now adding other Splash products to their portfolios. Our investment thesis on Copa di Vino has proven highly effective and is a model for future transactions that we anticipate will drive our growth,” said Robert Nistico, CEO of Splash. “SALT, a highly appealing brand serving one of the fastest-growing segments in spirits, will enhance Southern Eagle’s portfolio of over 700 alcoholic and non-alcoholic SKUs and we’re pleased to expand our business relationship with them.”

To view the full press release, visit https://ibn.fm/6nIa7

About Splash Beverage Group Inc.

Splash Beverage Group specializes in manufacturing, distribution, sales and marketing of various beverages across multiple channels. SBEV operates in both the non-alcoholic and alcoholic beverage segments, which the company believes leverages efficiencies and dilutes risk. SBEV believes its business model is unique as it only develops/accelerates brands it perceives to have highly visible preexisting brand awareness or pure category innovation. For more information about the company, visit www.SplashBeverageGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Splash Beverage Group Inc. SBEV | Leave a comment

MissionIRNewsBreaks – Infobird Software Co. Ltd. (NASDAQ: IFBD) Bringing Next-Gen SaaS, AI-Powered Solutions to Market

Infobird (NASDAQ: IFBD), a business-to-business (“B2B”) artificial intelligence (“AI”) solutions company, has constantly pushed the envelope in the development and launch of the next-generation software-as-a-service (“SaaS”) solutions. “Infobird is a SaaS provider focusing on AI-powered customer engagement solutions for the Chinese market. Its tech infrastructure is founded on cloud computing, machine learning, patented Voice over Internet Protocol (“VoIP”) application technologies, and AI,” reads a recent article. “Since its inception back in October 2001, the company has stayed committed to empowering clients with solutions specifically designed for the issues they face, all while increasing their revenue, reducing costs, enhancing service quality, and overall customer satisfaction. With its focus on SMEs, Infobird is trying to grow China into a leading SaaS market globally. By constantly innovating and tailoring its products and services to the customers, the company is slowly demystifying software and automation in business processes.”

To view the full article, visit https://ibn.fm/cIafJ

About Infobird Software Co. Ltd.

Infobird, headquartered in Beijing, China, is a software-as-a-service provider of innovative AI-powered or enabled customer engagement solutions. For more information about the company, visit www.Infobird.com.

NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Infobird Software Co. Ltd. IFBD | Leave a comment

MissionIRNewsBreaks – HempFusion Wellness Inc. (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO) Creating Brand Loyalty by ‘Doing It Right’

HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), a leader in the health and wellness cannabidiol (“CBD”) industry, has made compliance with regulatory standards for hemp-derived products worldwide one of its main priorities. This has opened doors to outlets for its products while many other CBD companies have struggled. In a June 29 Hemp Barons podcast, HempFusion co-founder and CEO Jason Mitchell and host Joy Beckerman extensively discussed the regulatory journey CBD dietary supplements, as well as OTC cosmetic topicals, have taken under guidance from the U.S. federal government. A recent article quotes Mitchel as saying, “The fact is, it’s really fun to do it right, because it’s challenging. And then when you see the consumer response that they get the result they want, and that you did it correctly . . . they’re going to have a tremendous amount of trust in you and have longevity in their support of your brand . . . and so that’s why we did it. We create this brand loyalty by virtue of doing it right.”

To view the full article, visit https://ibn.fm/1Y80Z

About HempFusion Wellness Inc.

HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retailers across all 50 U.S. states and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 46 SKUs, including tinctures, proprietary FDA Drug-listed over-the-counter (“OTC”) topicals, doctor/practitioner lines, and more. With a strong focus on R&D, HempFusion has an additional 30 products under development. HempFusion is a board member of the U.S. Hemp Roundtable, and HempFusion’s wholly owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex(TM) and are available in-store or by visiting HempFusion online at www.Hempfusion.com or www.Probulin.com.

NOTE TO INVESTORS: The latest news and updates relating to CBDHF are available in the company’s newsroom at https://ibn.fm/CBDHF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in HempFusion Wellness Inc. CBDHF | Leave a comment

Flora Growth Corp. (NASDAQ: FLGC) Is ‘One to Watch’

  • Flora Growth is uniquely positioned to achieve revenue growth, with a balance sheet supported by two successful financings and the recent launch of multiple operating divisions
  • The company boasts a robust M&A pipeline featuring strategic targets with near-term revenue growth opportunities and global distribution channels
  • Flora Growth is led by an exceptional management team featuring cannabis, CPG, and capital markets experts who have raised more than $3 billion in combined public financings
  • The company’s brand portfolio features 280+ products, 70+ medical and cosmetic licenses, and 2,500+ points of distribution across Latin America and the U.S.
  • Flora Growth has a healthy balance sheet with minimal debt; the company reported a cash balance of $25.3 million with long-term debt of just $0.7 million as of April 19, 2021
  • The company’s all-natural, outdoor cultivation operations allow for production costs below $0.06 per gram – roughly 60% lower than its closest peer

Flora Growth (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

For more information, visit the company’s website at www.FloraGrowth.ca

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Flora Growth Corp. FLGC | Leave a comment

The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) Finalizes Distribution Agreement with Largest Food Retailer in the Mid-Atlantic

  • WTER’s distribution agreement calls for Giant Food to carry select WTER Alkaline88(R) and A88 Infused(R) offerings 
  • The distributor will offer WTER beverages in all 164 locations.
  • Giant Food serves market of 60 million people with over $5 billion in sales. 

In an move illustrative of  its continued commitment to expansion and growth, The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) announced that it has partnered with Giant Food, the largest food retailer in the Mid-Atlantic region. The distribution agreement calls for Giant Food to carry select WTER Alkaline88 and A88 Infused offerings in all locations.

“This is our biggest win to date in the Mid-Atlantic region,” said WTER president and CEO Ricky Wright. “Giant Food is the largest retailer in that market of 60 million people with over $5 billion in sales. While many retailers will test one or two product offerings, we are pleased to announce that Giant Food is carrying six products from our Alkaline88 and A88 Infused lines in their 164 locations. 

“The products include our one-gallon and 1.5-liter bottles, and naturally flavored Watermelon, Raspberry, Blood Orange, and Lemon single serves,” he continued. “This year, we expect these and our other single serves to significantly increase their overall contribution to our top line. We couldn’t have hoped for a better start to our fiscal 2022 expansion into the Mid-Atlantic and Northeast regions than being on the shelves in Giant Food. This is just the beginning of a larger push into the remaining untapped markets in the U.S.”

Giant Food, a subsidiary of Ahold Delhaize, serves 164 stores in Maryland, Virginia, Delaware and Washington, DC. The company has been in operation for more than 80 years and has become an integral part of its customers’ lives and the communities it serves. The company’s commitment to providing its customers with the best is a perfect match with WTER’s dedication to offering the finest alkaline water products on the market. 

WTER’s Alkaline88 is known for its superior hydration with a perfect 8.8pH balance. The brand was developed to deliver what the company calls a Deliciously Smooth(TM) taste that encourages consumers to drink more and fully hydrate. The water’s ingredient deck is simple, easy to understand and free of buffers; it contains only two ingredients: purified water and Pink Himalayan Rock Salt.

With the Giant Food announcement, the Alkaline88(R) flagship brand of premium alkaline water is now available in 75,000 stores across all trades in the United States. 

For more information, visit the company’s website at www.TheAlkalineWaterCo.com and www.a88CBD.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in The Alkaline Water Company Inc. WTER | Leave a comment

Save Foods Inc. (NASDAQ: SVFD) Receives Seventh Global Patent for Proprietary Composition Method

  • Israeli Patent Office grants patent for new-generation, natural, disinfecting composition and method to protect edible matter from decay
  • Patent is further validation of SVFD’s technology, an important step in building company’s IP portfolio
  • Food waste is a social, humanitarian, economic and environment concern

Save Foods (NASDAQ: SVFD), an agri-food tech company focused on creating solutions to food waste and loss as well as food safety, has been granted its seventh global patent, protecting the company’s innovative ecofriendly product-treatment offerings (https://ibn.fm/XGHjr). The patent was granted by the Israeli Patent Office for SVFD’s new-generation natural disinfecting composition and method to protect edible matter from decay, ultimately extending extend shelf life and reduce waste.

“Israel is a world-leader in agricultural technologies and a major exporter of fresh produce,” said Dr. Neta Matis, vice president of R&D for Save Foods Ltd.’s Israel subsidiary. “Israel is a key jurisdiction for us to protect our proprietary technologies, and this patent is further validation of our technology and an important step in building an IP portfolio that ensures food safety reduce waste globally.”

The patent is Save Foods’ fourth issued patent in Israel and its seventh global patent. 

These patents are representative of the success of Save Foods’ dedication to addressing two major global issues: food waste and loss, and food safety. At face value, the implications of food waste are immense, with one recent report noting that “the amount of food waste in America alone is simply mind numbing, weighing in at 133 billion pounds and $161 billion worth of food in 2010. That means 31% of all food produced annually is wasted. As a subcategory, 644 million tons of fruit and vegetables, or 42% of total supply, is wasted annually” (https://ibn.fm/MOtc3). 

In fact, however, “food waste is a social, humanitarian, economic and environment concern. Understand that waste isn’t just what gets thrown away in a kitchen, grocery store or hotel. It also includes product that never leaves the farm or spoils during distribution. Collect those billions of pounds of waste, and there are enough calories to feed every undernourished person on the planet,” the report noted. “Now think about all the energy that was used, not to mention the trillions of gallons of water, to grow, harvest, package and transport the 133 billion pounds of fruit, vegetables, meat and more that ultimately ended up in the Dumpster. 

“If the United States, along with the rest of the world, genuinely wants to meet carbon reduction targets by 2030, all involved need to take a close look at food waste, considering it accounts for about 8% of global emissions. According to Project Drawdown, when accounting for deforestation for farmland and annual adoption of plant-rich diets, reducing food waste by 50% to 75% by 2050 would reduce carbon dioxide emissions by up to 95.1 gigatons.”

Save Foods offers the first natural product with potential to actually replace the different highly residual (hazardous) chemicals used today while also addressing the challenges of both food waste and food safety. The company’s core applications are ecofriendly, post-harvest treatments for fruits and vegetables. SVFD’s proprietary technologies reduce the need for conventional post-harvest fungicide by at least 50% — even entirely in some cases — can reduce food loss due to spoilage by up to 50%. 

The company is dedicated to delivering integrated solutions for improved safety, freshness and quality, every step of the way from field to fork. Collaborating closely with its customers, Save Foods develops new solutions that benefit the entire supply chain and improve the safety and quality of life of both workers and the consumers alike. 

For more information, visit the company’s website at www.SaveFoods.co

NOTE TO INVESTORS: The latest news and updates relating to SVFD are available in the company’s newsroom at https://ibn.fm/SVFD 

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Save Foods Inc. SVFD | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes VIRAL-A20-3 Pharmacokinetic Study on DehydraTECH(TM) Enabled Colchicine

  • The study indicated enhanced delivery of colchicine using the company’s proprietary DehydraTECH(TM) technology
  • Lexaria collaborates with the National Research Council (“NRC”), Canada’s leading research and technology organization
  • The company has 20 patents granted and over 50 pending patents in over 40 countries around the world
  • The global market for advanced drug delivery systems was valued at $231 billion in 2020 and is expected to grow to $310 billion by 2025

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that the tolerability and pharmacokinetic study entitled VIRAL-A20-3 was completed and yielded positive results. The study demonstrated that administration of colchicine using the company’s proprietary DehydraTECH(TM), formulation and processing, resulted in increased delivery, according to a company press release (https://ibn.fm/AXBcz). 

Colchicine is an approved therapeutic with anti-inflammatory effects primarily used to treat gout and cardiac conditions such as pericarditis. It was the latest of several drugs Lexaria tested with known SARS-CoV-2/COVID-19 antiviral properties after it showed potent effects in mitigating the cytokine storm associated with the virus. Additionally, colchicine is occasionally used to treat emergent pericarditis in children, which would make the substance potentially beneficial against this form of cardiac inflammation when it occurs as a side effect of mRNA COVID-19 vaccines.

The study was performed using Sprague-Dawley rats, with 20 dosed through oral gavage using DehydraTECH or control colchicine formulations. Performed by an independent, premier animal testing laboratory in the United States, the study evaluated both peak concentration and total drug delivery into the rodent’s bloodstream. As colchicine has a narrow therapeutic index, which means there is a marginal difference between toxic and non-toxic doses, Lexaria hopes that by using DehydraTECH it can improve its bioavailability beyond current levels of approximately 45 percent, which would potentially allow lower dosing requirements.

Lexaria’s DehydraTECH promotes fast-acting, less expensive, and more effective oral drug delivery. The method has been evaluated thoroughly through in vivo, in vitro, and human clinical testing. The company has shown, through animal studies, that DehydraTECH technology elevates the quantity of drugs delivered across the blood-brain barrier by as much as 1,900%. This research has initiated new patent applications and opened the possibilities for improved drug delivery.

The company has licensed its proprietary technology to multiple companies for use in different industries, including tobacco and nicotine products, cannabinoid beverages and edibles and more. Lexaria’s intellectual property portfolio consists of 20 patents granted and more than 50 patents pending in over 40 countries worldwide.

Lexaria is currently collaborating with the National Research Council (“NRC”), the Canadian government’s leading research and technology organization. The Company has already filed for patent protection for specific nicotine delivery, NSAIDs, vitamins, estrogen, testosterone, terpenes, cannabinoids, PDE5 inhibitors (like Viagra), tobacco, and more.

DehydraTECH is designed for formulating and delivering fat-soluble drugs and active ingredients, increasing their effectiveness and improving the way active pharmaceutical ingredients enter the bloodstream. The benefits of a DehydraTECH-enabled drug or consumer product are:

  • Delivery is sped up, making the effects felt by the consumer in a matter of minutes
  • The bioavailability is increased, making the delivery to the bloodstream much more effective and possibly requiring lower doses
  • Animal testing has evidenced that there is a significant increase in the amount of the formulation crossing the blood barrier
  • For consumer products, eliminates or reduces the need for sweeteners that are often used to mask the unwanted taste of the substance

This technology has the potential to revolutionize the global market for advanced drug delivery systems by changing the way treatments are administered and increasing overall bioabsorption and bioavailability. The drug delivery market is expected to reach a revenue of $310 billion by 2025 from $231 billion in 2020, marking a CAGR of 6.1% (https://ibn.fm/gGqYu). Right now, one of three areas of focus for Lexaria is on the antiviral drug market, which is anticipated to reach $52.1 billion in 2021 and grow to $66.7 billion by 2025. 

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Small Cap News | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures $3.8M Through Warrant Exercises

Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of US$3,817,643 from the exercise of share purchase warrants. According to the update, the company issued the warrants pursuant to its January 2021 public underwritten offering. The shares and warrants issued thereunder were registered pursuant to a Form S-1 Registration Statement (No. 333-250326), as amended, and a Form S-1MEF Registration Statement (No. 333-252031). The warrants were exercised into 580,189 shares of voting common stock of the company, each at an exercise price of US$6.58. The company will utilize all proceeds received from the warrant exercises for the continued advancement of its investigational research program and for general corporate purposes. With this additional capital, Lexaria Bioscience Corp. believes its business plan objectives and all operations are now funded well into the year 2022.

To view the full press release, visit https://ibn.fm/MUPGl

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-viral drugs, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 20 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Lexaria Bioscience Corp. LEXX, MissionIRNewsBreaks | Leave a comment